Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma Journal Article


Authors: Kikuchi, E.; Margulis, V.; Karakiewicz, P. I.; Roscigno, M.; Mikami, S.; Lotan, Y.; Remzi, M.; Bolenz, C.; Langner, C.; Weizer, A.; Montorsi, F.; Bensalah, K.; Koppie, T. M.; Fernández, M. I.; Raman, J. D.; Kassouf, W.; Wood, C. G.; Suardi, N.; Oya, M.; Shariat, S. F.
Article Title: Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma
Abstract: Purpose: To assess the association of lymphovascular invasion (LVI) with cancer recurrence and survival in a large international series of patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Patients and Methods: Data were collected on 1,453 patients treated with RNU at 13 academic centers and combined into a relational database. Pathologic slides were rereviewed by genitourinary pathologists according to strict criteria. LVI was defined as presence of tumor cells within an endothelium-lined space. Results: LVI was observed in 349 patients (24%). Proportion of LVI increased with advancing tumor stage, high tumor grade, presence of tumor necrosis, sessile tumor architecture, and presence of lymph node metastasis (all P < .001). LVI was an independent predictor of disease recurrence and survival (P < .001 for both). Addition of LVI to the base model (comprising pathologic stage, grade, and lymph node status) marginally improved its predictive accuracy for both disease recurrence and survival (1.1%, P = .03; and 1.7%, P < .001, respectively). In patients with negative lymph nodes and those in whom a lymphadenectomy was not performed (n = 1,313), addition of LVI to the base model improved the predictive accuracy of the base model for both disease recurrence and survival by 3% (P < .001 for both). In contrast, LVI was not associated with disease recurrence or survival in node-positive patients (n = 140). Conclusion: LVI was an independent predictor of clinical outcomes in nonmetastatic patients who underwent RNU for UTUC. Assessment of LVI may help identify patients who could benefit from multimodal therapy after RNU. After confirmation, LVI should be included in staging of UTUC. © 2008 by American Society of Clinical Oncology.
Keywords: cancer survival; controlled study; major clinical study; cancer recurrence; cancer staging; outcome assessment; lymph node metastasis; lymph nodes; lymphadenectomy; recurrence; cancer invasion; endothelium cell; lymphatic system; urologic neoplasms; endothelium, vascular; nephroureterectomy; tumor cell; neoplasm invasiveness; urinary tract carcinoma; blood vessels
Journal Title: Journal of Clinical Oncology
Volume: 27
Issue: 4
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2009-02-01
Start Page: 612
End Page: 618
Language: English
DOI: 10.1200/jco.2008.17.2361
PUBMED: 19075275
PROVIDER: scopus
PMCID: PMC2737380
DOI/URL:
Notes: --- - "Cited By (since 1996): 11" - "Export Date: 30 November 2010" - "CODEN: JCOND" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Shahrokh Shariat
    68 Shariat